- Home
- AMD vs AMGN Comparison
AMD vs AMGN Comparison
Compare AMD & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMD
- AMGN
- Stock Information
- Founded
- AMD 1969
- AMGN 1980
- Country
- AMD United States
- AMGN United States
- Employees
- AMD N/A
- AMGN N/A
- Industry
- AMD Semiconductors
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMD Technology
- AMGN Health Care
- Exchange
- AMD Nasdaq
- AMGN Nasdaq
- Market Cap
- AMD 179.5B
- AMGN 156.2B
- IPO Year
- AMD 1972
- AMGN N/A
- Fundamental
- Price
- AMD $110.73
- AMGN $288.18
- Analyst Decision
- AMD Buy
- AMGN Buy
- Analyst Count
- AMD 35
- AMGN 21
- Target Price
- AMD $138.07
- AMGN $323.62
- AVG Volume (30 Days)
- AMD 44.0M
- AMGN 3.2M
- Earning Date
- AMD 05-06-2025
- AMGN 05-01-2025
- Dividend Yield
- AMD N/A
- AMGN 3.30%
- EPS Growth
- AMD 99.41
- AMGN 56.16
- EPS
- AMD 1.37
- AMGN 10.94
- Revenue
- AMD $27,750,000,000.00
- AMGN $34,126,000,000.00
- Revenue This Year
- AMD $23.86
- AMGN $7.62
- Revenue Next Year
- AMD $17.19
- AMGN $1.88
- P/E Ratio
- AMD $80.84
- AMGN $26.34
- Revenue Growth
- AMD 21.71
- AMGN 15.56
- 52 Week Low
- AMD $76.48
- AMGN $253.30
- 52 Week High
- AMD $187.28
- AMGN $346.85
- Technical
- Relative Strength Index (RSI)
- AMD 55.59
- AMGN 58.41
- Support Level
- AMD $107.67
- AMGN $269.10
- Resistance Level
- AMD $115.54
- AMGN $276.90
- Average True Range (ATR)
- AMD 3.29
- AMGN 5.90
- MACD
- AMD -0.31
- AMGN 2.48
- Stochastic Oscillator
- AMD 24.13
- AMGN 97.70
About AMD Advanced Micro Devices Inc.
Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications. AMD's traditional strength was in central processing units and graphics processing units used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array leader Xilinx to diversify its business and augment its opportunities in key end markets such as data center and automotive.
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.